Drugs / PRN1371
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02608125 | Oct 2015 → Jun 2020 | urothelial carcinoma | Principia Biopharma, a Sanofi Company | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PRN1371 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02608125 ↗ |
| Action | Inhibit | “PRN1371, a FGFR 1-4 Kinase inhibitor” NCT02608125 ↗ |
| Modality | Small molecule | “PRN1371, a FGFR 1-4 Kinase inhibitor” NCT02608125 ↗ |